Factory Mutual Insurance Co. Boosts Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. boosted its position in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 59.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 85,400 shares of the medical research company’s stock after buying an additional 31,900 shares during the quarter. Factory Mutual Insurance Co.’s holdings in Amgen were worth $24,597,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Southland Equity Partners LLC increased its holdings in shares of Amgen by 2.3% in the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock worth $443,000 after buying an additional 34 shares during the last quarter. Acropolis Investment Management LLC boosted its position in Amgen by 3.5% in the 4th quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock valued at $288,000 after buying an additional 34 shares during the period. Opal Wealth Advisors LLC boosted its position in Amgen by 1.9% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $538,000 after buying an additional 34 shares during the period. FORVIS Wealth Advisors LLC boosted its position in Amgen by 1.4% in the 4th quarter. FORVIS Wealth Advisors LLC now owns 2,578 shares of the medical research company’s stock valued at $743,000 after buying an additional 35 shares during the period. Finally, Evanson Asset Management LLC boosted its position in Amgen by 2.1% in the 4th quarter. Evanson Asset Management LLC now owns 1,666 shares of the medical research company’s stock valued at $480,000 after buying an additional 35 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Down 0.4 %

Shares of NASDAQ:AMGN traded down $0.98 during mid-day trading on Wednesday, reaching $275.23. 298,578 shares of the company were exchanged, compared to its average volume of 2,966,054. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The firm has a market cap of $147.50 billion, a price-to-earnings ratio of 22.11, a P/E/G ratio of 2.67 and a beta of 0.58. The firm’s 50-day simple moving average is $288.00 and its 200 day simple moving average is $281.45. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $329.72.

Amgen (NASDAQ:AMGNGet Free Report) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. The firm had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm’s quarterly revenue was up 19.8% on a year-over-year basis. During the same quarter last year, the company posted $4.09 EPS. Equities research analysts forecast that Amgen Inc. will post 19.48 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a $2.25 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a yield of 3.27%. Amgen’s dividend payout ratio is presently 72.06%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several recent research reports. Royal Bank of Canada restated an “outperform” rating and issued a $329.00 price target on shares of Amgen in a report on Wednesday. UBS Group reduced their price objective on shares of Amgen from $315.00 to $314.00 and set a “neutral” rating for the company in a research note on Monday, January 29th. SVB Leerink lowered shares of Amgen from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $324.00 to $318.00 in a research note on Wednesday, February 7th. Daiwa Capital Markets upgraded shares of Amgen from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $264.00 to $320.00 in a research note on Thursday, December 21st. Finally, StockNews.com lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $295.30.

Check Out Our Latest Stock Analysis on AMGN

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Read More

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.